Related Experiment Video

Updated: May 27, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Targeting the androgen receptor--theory and practice

Robert Dreicer1, Martin Gleave, Adam S Kibel

  • 1Department of Solid Tumor Oncology; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Urology
|November 8, 2011
PubMed

Insights

Recent advances improve understanding of androgen receptor biology and castrate-resistant prostate cancer. New hormonal therapies and better assays confirm ongoing testosterone suppression as the standard of care.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • The androgen receptor (AR) plays a crucial role in prostate cancer development and progression.
  • Castrate-resistant prostate cancer (CRPC) remains a significant clinical challenge.
  • Understanding AR biology has advanced significantly over the past two decades.

Purpose of the Study:

  • To review the current knowledge of androgen receptor biology in prostate cancer.
  • To discuss advancements in assessing disease progression and CRPC.
  • To highlight the evolution of hormonal therapy and terminology in prostate cancer management.

Main Methods:

  • Comprehensive literature review of studies on androgen receptor biology.
  • Analysis of clinical data regarding disease progression assessment.
  • Evaluation of the development and efficacy of novel hormonal therapy agents.

Main Results:

  • Improved understanding of AR signaling pathways and their role in CRPC.
  • Development of a new generation of hormonal therapy agents for androgen deprivation.
  • Enhanced assays for monitoring disease progression and treatment response.

Conclusions:

  • Ongoing suppression of testosterone is the established standard of care for prostate cancer.
  • The terms "hormone-refractory" and "androgen-independent" prostate cancer should be reconsidered.
  • Continued research into AR biology will likely yield further therapeutic advancements.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Hormone Receptors01:08

Intracellular Hormone Receptors

Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...